Diabetes, Diabetes Mellitus, Type 1
Conditions
Brief summary
This trial is conducted in Europe. The aim of this trial is to investigate Pharmacodynamics (the effect of the investigated drug on the body) , Pharmacokinetics (the exposure of the trial drug in the body), and Safety of NNC0143-0406 in Subjects with Type 1 Diabetes Mellitus
Interventions
DRUGNNC0143-0406
Administered subcutaneously (s.c. under the skin)
DRUGInsulin Aspart
Administered subcutaneously (s.c. under the skin)
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Male or female aged 18-55 years (both inclusive) at the time of signing informed consent * Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening * Treated with continuous subcutaneous insulin infusion at least 90 days prior to the day of screening
Exclusion criteria
* Known or suspected hypersensitivity to trial product(s) or related products * Males who are sexually active and not surgically sterilised (vasectomy or otherwise) and their partners that are not using a highly effective contraception method, from randomisation until 90 days after dosing, such as double barrier contraception (e.g. condom and spermicide) or combination of either an oral ontraceptive, a contraceptive patch, a diaphragm or intrauterine device, together with a physical barrier such as condom. Male subjects must also agree to refrain from sperm donation from randomisation until 90 days after last dosing * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) (adequate contraceptive measures are defined as sterilisation, hormonal intrauterine device, oral contraceptives, condom with spermicide sexual abstinence or vasectomised partner)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ratio of suppression of endogenous glucose production relative to total glucose lowering effect | Two weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Number of treatment emergent adverse events | Time of first trial product administration to 7 days (7 times 24 hours) after last trial product administration |
Countries
Austria
Outcome results
None listed